<div id="readability-page-1"><div> By Adriano Marchese <pre></pre> Iovance Biotherapeutics shares rose after the company received positive data from a clinical trial of its cancer treatment. Shares traded 11% higher ahead of the morning bell at $2.18. The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%. Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said. <pre></pre> Write to Adriano Marchese at adriano.marchese@wsj.com <pre></pre> (END) Dow Jones Newswires November 03, 2025 09:40 ET (14:40 GMT)Copyright (c) 2025 Dow Jones &amp; Company, Inc.</div></div>

IOVA

Iovance Biotherapeutics shares rose 11% to $2.18 in premarket trading following positive Phase 2 trial results for its cancer treatment, lifileucel. Approximately 26% of patients responded to the treatment, with a disease-control rate of 72%. The company plans to present more data in 2026 and aims to file for a biologics license application with the FDA next year, targeting a potential launch in the second half of 2027.

Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug